Idenix Pharmaceuticals (IDIX)

[go seek]

listened again, drug interaction study fully enrolled

Co. on target to submit a late breaker abstract to EASL in 2 weeks concerning interaction study (Abstract on the website @ 1 March) ... will report on the primary endpoint at (1) month @ the 2 March earnings call.

"We remain extremely encouraged by this study." very good safety and tolerance, actually very low discontinuation rate, (very low single digit)... w/ this 12 week data we will be in good stead to sit w/ regulatory authorities and move to P3 in 2H 2007 in HCV treatment naive.